We serve Chemical Name:4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline CAS:882670-69-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
CAS.NO:882670-69-1
Synonyms:4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline;Benzenamine, 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
Molecular Formula:C13H20BNO2
Molecular Weight:233.114
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:366.2±35.0 °C at 760 mmHg
Density:1.0±0.1 g/cm3
Index of Refraction:1.515
PSA:44.48000
Exact Mass:233.158707
LogP:2.45760
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzenamine, 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline Use and application,4-Methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline technical grade,usp/ep/jp grade.
Related News: The plant will complement Recipharm’s existing sites in France, Germany and Italy and will be focused on securing approvals from regulators in Europe and the U.S. 1H-Pyrazole-4-carboxamide,N-[2-cyano-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]-5-methyl-1-[4-(trifluoromethyl)phenyl]- manufacturers IBI321 was discovered through a collaboration between Innovent and Eli Lilly and Company and has been developed in China by Innovent. The IND for IBI321 has been approved by the NMPA in China, and clinical trials in China are actively being conducted. DECAPRENOLPHOSPHATEAMMONIUM suppliers Despite the $13 million first-quarter hit from the rate cut, iRhythm grew revenue year over year by 17% to $74.3 million in the quarter. iRhythm’s net losses for the quarter totaled $27.8 million, compared to a net loss of $9.1 million in the first quarter of 2020. iodo-dimethyl-diphenyl-λ<sup>5</sup>-phosphane vendor & factory.
